The Health Insurance Organisation (HIO) wishes to inform beneficiaries that from Friday 15/07/2022 the following drugs of the SGLT-2 inhibitor class for patients with type 2 diabetes mellitus will be available from the GHS:
- FORXIGA TABLET 10MG
- INVOKANA TABLET 100MG and INVOKANA TABLET 300MG
- JARDIANCE TABLET 10MG and JARDIANCE TABLET 25MG
- STEGLATRO TABLET 15MG and STEGLATRO TABLET 5MG
- SYNJARDY TABLET 12.5MG/1000MG, SYNJARDY TABLET 12.5MG/850MG, SYNJARDY TABLET 5MG/1000MG and SYNJARDY TABLET 5MG/850MG
- VOKANAMET TABLET 150MG/1000MG, VOKANAMET TABLET 150MG/850MG, VOKANAMET TABLET 50MG/1000MG, VOKANAMET TABLET 50MG/850MG
- XIGDUO TABLET 5MG/1000MG, XIGDUO TABLET 5MG/850MG
The prescription via the GHS Information System of the above pharmaceutical products will be possible provided that:
- made by Adult Personal Physicians, Geriatricians and Endocrinologists
- beneficiaries meet the protocol criteria.
Beneficiaries are requested to contact their treating physician to find out whether they meet these criteria.
(NΓ/ΣX)
Contents of this article including associated images are owned by PIO
Views & opinions expressed are those of the author and/or PIO
Source